We sincerely appreciate all our investors who kindly care and support the Throne’s Crowdfunding Campaign at StartEngine, leading to the initiation of our clinical trials of Stem Cell Educator therapy

We sincerely appreciate all our investors who kindly care and support the Throne’s Crowdfunding Campaign at StartEngine, leading to the initiation of our clinical trials of Stem Cell Educator therapy. This

We are so thankful for all of our investors so far and sincerely appreciate all your generosities to support the clinical trials of Stem Cell Educator therapy to treat type

We are honored to announce that Throne Biotechnologies (Throne) is one of the awardees of the “5 Best BioTech Companies To Watch“ by The Silicon Review.

Type 2 diabetes (T2D) is the most common type of diabetes, with prevalence increasing worldwide due to the popularization of a Western lifestyle characterized by overnutrition and limited exercise. According

NOW LIVE: We are very excited that our equity crowdfunding campaign is live on Start Engine! The Press Release of this campaign has been widely published in major social media

To support the United States FDA-approved phase 2 clinical trials of Stem Cell Educator therapy and find a cure for type 1 diabetes and other autoimmune diseases, we are excited

We are delighted to announce that Dr. Yong Zhao, founder and CEO at Throne, will give an oral presentation about the Stem Cell Educator therapy in type 1 diabetes at

Type 1 diabetes (T1D) is an autoimmune disease that causes a deficit of pancreatic islet beta cells. Millions of individuals worldwide have T1D, and its incidence increases during the pandemic

Throne Biotechnologies (Throne) is developing Stem Cell Educator therapy to treat type 1 diabetes (T1D) and other autoimmune/inflammation-associated diseases. T1D is an autoimmune disease that causes a deficit of islet